ETFs Are Net Sellers of Pacira BioSciences (PCRX) on Oct. 22
Six ETFs sold Pacira BioSciences (PCRX) shares on Oct. 22, totaling $10.5 million in net outflows. This extends a five-session trend of ETF selling. The largest sellers were DFSV, DFAT, and DFAS. Pacira has a market cap of $1.5 billion and reported a 17.5% revenue increase over the past year. The stock trades at a P/E of 104.96 and has returned 40.73% year to date.
How this was made
The 30-second read
Why it matters
The main tradable signal is flow direction and persistence: net outflows of $10.5M on Oct. 22 extend a five-session streak of ETF net selling, which can weigh on near-term sentiment and technicals.
Market read
Flow data provides a short-term sentiment/positioning read, but it is not a company fundamental catalyst.
What to watch
The article does not provide price reaction, NAV context, or whether the selling is concentrated in one or two funds beyond stake reductions, limiting inference about sustained demand.
Background
The article is an ETF flow tracker for Pacira BioSciences, summarizing how many ETFs bought versus sold PCRX shares on Oct. 22 and over prior sessions.
Ticker impact
Article reports ETF flows into Pacira BioSciences, showing six ETFs selling and a $10.5M net outflow on Oct. 22.
Likely downside bias as traders interpret continued ETF outflows as reduced marginal buying.
The piece quantifies same-day net outflow ($10.5M) and notes negative ETF activity for five straight sessions, which can influence short-term flows and sentiment even without company-specific fundamentals.
Market effects
Could modestly affect sentiment toward specialty pharma names if ETF flow weakness is interpreted as risk-off within the group.
Primarily US-listed ETF flow sentiment, limited broader regional spillover.
Low, as the catalyst is domestic ETF positioning rather than global macro or cross-border fundamentals.
Counterpoint
ETF net selling may reflect index rebalancing, liquidity management, or temporary fund-level constraints rather than a fundamental reassessment of Pacira.
Key entities
- companyPacira BioSciences
Specialty pharmaceutical company focused on non-opioid pain management and regenerative health.
- investor_typeETFs
Six ETFs bought and six sold PCRX shares on Oct. 22, producing a net outflow.
